Comparative Pharmacology
Head-to-head clinical analysis: GANTRISIN versus TRYSUL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANTRISIN versus TRYSUL.
GANTRISIN vs TRYSUL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydropteroic acid, thereby inhibiting bacterial folate synthesis and nucleic acid production.
Trypanocidal agent; forms a complex with DNA and inhibits nucleic acid synthesis.
2-4 g orally initially, then 4-8 g daily in 3-6 divided doses
2 tablets (each containing sulfamethoxazole 400 mg and trimethoprim 80 mg) orally every 12 hours for 10-14 days.
None Documented
None Documented
7-12 hours (mean 10 hours); prolonged to 20-50 hours in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life: 8-10 hours in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 70% as unchanged drug; hepatic metabolism: 30% as acetylated metabolites; biliary: <3%
Renal: approximately 70-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: 15-20% as metabolites; small amount in feces.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic